Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: A cross-sectional multicenter study.
Détails
ID Serval
serval:BIB_70946CE379F4
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: A cross-sectional multicenter study.
Périodique
Journal of affective disorders
Collaborateur⸱rice⸱s
CSA Study Group
Contributeur⸱rice⸱s
Adès J., Alezrah C., Amado I., Amar G., Andréi O., Arbault D., Archambault G., Aurifeuille G., Barrière S., Béra-Potelle C., Blumenstock Y., Bardou H., Bareil-Guérin M., Barrau P., Barrouillet C., Baup E., Bazin N., Beaufils B., Ben Ayed J., Benoit M., Benyacoub K., Bichet T., Blanadet F., Blanc O., Blanc-Comiti J., Boussiron D., Bouysse A.M., Brochard A., Brochart O., Bucheron B., Cabot M., Camus V., Chabannes J.M., Charlot V., Charpeaud T., Clad-Mor C., Combes C., Comisu M., Cordier B., Costi F., Courcelles J.P., Creixell M., Cuche H., Cuervo-Lombard C., Dammak A., Da Rin D., Denis J.B., Denizot H., Deperthuis A., Diers E., Dirami S., Donneau D., Dreano P., Dubertret C., Duprat E., Duthoit D., Fernandez C., Fonfrede P., Freitas N., Gasnier P., Gauillard J., Getten F., Gierski F., Godart F., Gourevitch R., Grassin Delyle A., Gremion J., Gres H., Griner V., Guerin-Langlois C., Guggiari C., Guillin O., Hadaoui H., Haffen E., Hanon C., Haouzir S., Hazif-Thomas C., Heron A., Hubsch B., Jalenques I., Januel D., Kaladjian A., Karnycheff J.F., Kebir O., Krebs M.O., Lajugie C., Leboyer M., Legrand P., Lejoyeux M., Lemaire V., Leroy E., Levy-Chavagnat D., Leydier A., Liling C., Llorca P.M., Loeffel P., Louville P., Lucas Navarro S., Mages N., Mahi M., Maillet O., Manetti A., Martelli C., Martin P., Masson M., Maurs-Ferrer I., Mauvieux J., Mazmanian S., Mechin E., Mekaoui L., Meniai M., Metton A., Mihoubi A., Miron M., Mora G., Niro Adès V., Nubukpo P., Omnes C., Papin S., Paris P., Passerieux C., Pellerin J., Perlbarg J., Perron S., Petit A., Petitjean F., Portefaix C., Pringuey D., Radtchenko A., Rahiou H., Raucher-Chéné D., Rauzy A., Reinheimer L., Renard M., René M., Rengade C.E., Reynaud P., Robin D., Rodrigues C., Rollet A., Rondepierre F., Rousselot B., Rubingher S., Saba G., Salvarelli J.P., Samuelian J.C., Scemama-Ammar C., Schurhoff F., Schuster J.P., Sechter D., Segalas B., Seguret T., Seigneurie A.S., Semmak A., Slama F., Taisne S., Taleb M., Terra J.L., Thefenne D., Tran E., Tourtauchaux R., Vacheron M.N., Vandel P., Vanhoucke V., Venet E., Verdoux H., Viala A., Vidon G., Vitre M., Vurpas J.L., Wagermez C., Walter M., Yon L., Zendjidjian X.
ISSN
1573-2517 (Electronic)
ISSN-L
0165-0327
Statut éditorial
Publié
Date de publication
01/12/2019
Peer-reviewed
Oui
Volume
259
Pages
210-217
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
Although lithium is widely used in current practice to treat bipolar disorder (BD) and treatment-resistant major depressive disorder (MDD) among older adults, little is known about its efficacy and tolerability in this population, which is generally excluded from randomized clinical trials. The objective of this study was to evaluate the efficacy and tolerability of long-term use of lithium among older adults with BD and MDD.
Data from the Cohort of individuals with Schizophrenia and mood disorders Aged 55 years or more (CSA) were used. Two groups of patients with BD and MDD were compared: those who were currently receiving lithium versus those who were not. The effects of lithium on psychiatric (i.e., depressive symptoms severity, perceived clinical severity, rates of psychiatric admissions in the past-year), geriatric (overall and cognitive functioning) and physical outcomes (i.e., rates of non-psychiatric medical comorbidities and general hospital admissions in the past-year) were evaluated. All analyses were adjusted for age, sex, duration of disorder, diagnosis, smoking status, alcohol use, and use of antipsychotics, antiepileptics or antidepressants.
Among the 281 older participants with BD or MDD, 15.7% were taking lithium for a mean duration of 12.5(SD = 11.6) years. Lithium use was associated with lower intensity of depressive symptoms, reduced perceived clinical global severity and lower benzodiazepine use (all p < 0.05), without being linked to greater rates of medical comorbidities, except for hypothyroidism.
Data were cross-sectional and data on lifetime history of psychotropic medications was not assessed.
Our results suggest that long-term lithium use may be efficient and relatively well-tolerated in older adults with BD or treatment-resistant MDD.
Data from the Cohort of individuals with Schizophrenia and mood disorders Aged 55 years or more (CSA) were used. Two groups of patients with BD and MDD were compared: those who were currently receiving lithium versus those who were not. The effects of lithium on psychiatric (i.e., depressive symptoms severity, perceived clinical severity, rates of psychiatric admissions in the past-year), geriatric (overall and cognitive functioning) and physical outcomes (i.e., rates of non-psychiatric medical comorbidities and general hospital admissions in the past-year) were evaluated. All analyses were adjusted for age, sex, duration of disorder, diagnosis, smoking status, alcohol use, and use of antipsychotics, antiepileptics or antidepressants.
Among the 281 older participants with BD or MDD, 15.7% were taking lithium for a mean duration of 12.5(SD = 11.6) years. Lithium use was associated with lower intensity of depressive symptoms, reduced perceived clinical global severity and lower benzodiazepine use (all p < 0.05), without being linked to greater rates of medical comorbidities, except for hypothyroidism.
Data were cross-sectional and data on lifetime history of psychotropic medications was not assessed.
Our results suggest that long-term lithium use may be efficient and relatively well-tolerated in older adults with BD or treatment-resistant MDD.
Mots-clé
Aged, Aging/drug effects, Antidepressive Agents/adverse effects, Antidepressive Agents/therapeutic use, Antipsychotic Agents/adverse effects, Antipsychotic Agents/therapeutic use, Benzodiazepines/therapeutic use, Bipolar Disorder/drug therapy, Comorbidity, Cross-Sectional Studies, Depression, Depressive Disorder, Major/drug therapy, Depressive Disorder, Treatment-Resistant/drug therapy, Female, Hospitalization/statistics & numerical data, Humans, Lithium Compounds/adverse effects, Lithium Compounds/therapeutic use, Male, Middle Aged, Bipolar disorder, Effectiveness, Lithium, Long-term, Major depressive disorder, Older adults, Tolerability
Pubmed
Web of science
Open Access
Oui
Création de la notice
05/05/2023 16:01
Dernière modification de la notice
13/05/2023 5:51
Données d'usage
